IMMUNIC, INC. Files 8-K Report
Ticker: IMUX · Form: 8-K · Filed: Feb 20, 2025 · CIK: 1280776
| Field | Detail |
|---|---|
| Company | Immunic, INC. (IMUX) |
| Form Type | 8-K |
| Filed Date | Feb 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, financials
TL;DR
IMMUNIC, INC. filed an 8-K, mostly boilerplate. No major news yet.
AI Summary
On February 20, 2025, IMMUNIC, INC. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text. The company, formerly known as VITAL THERAPIES INC, is incorporated in Delaware and has its principal executive offices in New York.
Why It Matters
This 8-K filing indicates IMMUNIC, INC. is fulfilling its reporting obligations, though it does not disclose any new material events at this time. Investors should monitor future filings for significant updates.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not contain information that suggests an immediate change in risk for the company.
Key Numbers
- 001-36201 — SEC File Number (Identifies the company's filing with the SEC)
- 56-2358443 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- IMMUNIC, INC. (company) — Registrant
- VITAL THERAPIES INC (company) — Former company name
- February 20, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- New York (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the 'ITEM INFORMATION' section.
When was this 8-K report filed?
This 8-K report was filed on February 20, 2025.
What was IMMUNIC, INC.'s former company name?
IMMUNIC, INC.'s former company name was VITAL THERAPIES INC.
In which state is IMMUNIC, INC. incorporated?
IMMUNIC, INC. is incorporated in Delaware.
Does this filing report any specific material events?
Based on the provided text, this filing primarily concerns financial statements and exhibits and does not explicitly detail any specific material events beyond routine reporting.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 20, 2025 regarding IMMUNIC, INC. (IMUX).